 |
Products |  |
Diseases | | Products |
|
Trials |  |
News |  |
- | KNX100 / Kinoxis Therapeutics
Enrollment open, Trial initiation date: Study to Examine the Safety, Tolerability, and Efficacy of KNX100 in the Treatment of Subjects with Agitation Associated with Dementia (EUDRACT) - Sep 13, 2024
P2, N=60, Recruiting, Sponsor: Kinoxis Therapeutics Pty Ltd
Not yet recruiting --> Recruiting
- | KNX100 / Kinoxis Therapeutics
New P2 trial: Study to Examine the Safety, Tolerability, and Efficacy of KNX100 in the Treatment of Subjects with Agitation Associated with Dementia (EUDRACT) - Jun 21, 2024
P2, N=60, Not yet recruiting, Sponsor: Kinoxis Therapeutics Pty Ltd
- ||| KNX100 / Kinoxis Therapeutics
Trial completion, Trial completion date: KTX101: A Phase 1 Study Investigating the Safety, Tolerability and Pharmacokinetics of KNX100 in Healthy Volunteers (clinicaltrials.gov) - Dec 13, 2023
P1, N=64, Completed, Sponsor: Kinoxis Therapeutics Pty Ltd
Not yet recruiting --> Recruiting Recruiting --> Completed | Trial completion date: Dec 2023 --> Sep 2023
- || KNX100 / Kinoxis Therapeutics
Enrollment change, Trial completion date, Trial primary completion date: KTX101: A Phase 1 Study Investigating the Safety, Tolerability and Pharmacokinetics of KNX100 in Healthy Volunteers (clinicaltrials.gov) - Feb 15, 2023
P1, N=64, Recruiting, Sponsor: Kinoxis Therapeutics Pty Ltd
Recruiting --> Completed | Trial completion date: Dec 2023 --> Sep 2023 N=40 --> 64 | Trial completion date: Sep 2023 --> Dec 2023 | Trial primary completion date: Nov 2022 --> Sep 2023
- || KNX100 / Kinoxis Therapeutics
Enrollment open: KTX101: A Phase 1 Study Investigating the Safety, Tolerability and Pharmacokinetics of KNX100 in Healthy Volunteers (clinicaltrials.gov) - Apr 14, 2022
P1, N=40, Recruiting, Sponsor: Kinoxis Therapeutics Pty Ltd
N=40 --> 64 | Trial completion date: Sep 2023 --> Dec 2023 | Trial primary completion date: Nov 2022 --> Sep 2023 Not yet recruiting --> Recruiting
- || KNX100 / Kinoxis Therapeutics
Enrollment change, Trial completion date, Trial initiation date, Trial primary completion date: KTX101: A Phase 1 Study Investigating the Safety, Tolerability and Pharmacokinetics of KNX100 in Healthy Volunteers (clinicaltrials.gov) - Jan 24, 2022
P1, N=40, Not yet recruiting, Sponsor: Kinoxis Therapeutics Pty Ltd
Not yet recruiting --> Recruiting N=64 --> 40 | Trial completion date: Sep 2022 --> Sep 2023 | Initiation date: Sep 2021 --> Feb 2022 | Trial primary completion date: Jun 2022 --> Nov 2022
- | KNX100 / Kinoxis Therapeutics
New P1 trial: KTX101: A Phase 1 Study Investigating the Safety, Tolerability and Pharmacokinetics of KNX100 in Healthy Volunteers (clinicaltrials.gov) - May 25, 2021
P1, N=64, Not yet recruiting, Sponsor: Kinoxis Therapeutics Pty Ltd